Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.45 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.45 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.45 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | EPM2A | O95278 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
| ▸ | PTPN9 | P43378 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10464778 | 0.82 | GAA (0.57) | MEN1KMT2ANPC1MAPTGAA | |
| SCHEMBL10464324 | 0.80 | VCP (0.58) | MEN1KMT2AMAPTGAAMAPK1 | |
| SCHEMBL18342110 | 0.76 | MEN1 (0.49) | MEN1KMT2ANPC1PKMMAPT | |
| SCHEMBL18342167 | 0.76 | MAPT (0.46) | MEN1KMT2ANPC1PKMMAPT | |
| SCHEMBL18342060 | 0.76 | CSNK2A1 (0.56) | MEN1KMT2ANPC1PKMMAPT | |
| SCHEMBL30956257 | 0.74 | CCR4 (0.55) | MEN1KMT2ANPC1PKMMAPT | |
| SCHEMBL29274275 | 0.74 | CCR4 (0.55) | MEN1KMT2ANPC1PKMMAPT | |
| SCHEMBL1887057 | 0.73 | MEN1 (0.77) | MEN1KMT2ANPC1PKMMAPT | |
| SCHEMBL18342066 | 0.73 | KDM1A (0.55) | MEN1KMT2ANPC1PKMMAPT | |
| SCHEMBL18003087 | 0.73 | ALDH1A1 (0.64) | MEN1KMT2ANPC1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922394-B | 3-tetrazolyl-benzene-1, 2-disulfonamide derivatives as metallo-beta-lactamase inhibitors | 默沙东公司 | 2021-07-13 | — | — | CN | disclosed |
| EP-3313832-B1 | 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-02-24 | — | — | EP | disclosed |
| US-10544130-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190144432-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-05-16 | — | — | US | disclosed |
| US-10221163-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180244656-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-08-30 | — | — | US | disclosed |
| EP-3313832-A1 | 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-05-02 | — | — | EP | disclosed |
| CN-107922394-A | 3 tetrazole radical benzene, 1,2 disulfonic acid amide derivative as metal beta lactamase restrainer | 默沙东公司 | 2018-04-17 | — | — | CN | disclosed |
| WO-2016210215-A1 | 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544130-B2 | Metallo-beta-lactamase inhibitors | MLX, ZFX, MMP12 | MEN1 417/4885KMT2A 1095/4885NPC1 860/4885 |
| US-10221163-B2 | Metallo-beta-lactamase inhibitors | MLX, ZFX, MMP12 | MEN1 433/4885KMT2A 1103/4885NPC1 952/4885 |
| US-20190144432-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MLX, ZFX, MMP12 | MEN1 417/4885KMT2A 1095/4885NPC1 860/4885 |
| US-20180244656-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MLX, ZFX, MMP12 | MEN1 433/4885KMT2A 1103/4885NPC1 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.